Position:
The Director of Metabolic Conditions is a key member of the Moonwalk R&D team, driving the company’s translational science in metabolic conditions including obesity and NASH. In this role, you will oversee and lead Moonwalk’s biological and translational research in the area of metabolic conditions, working closely with the platform technology team to leverage Moonwalk’s epigenome engineering platform. You will also work closely with the leadership team to align research programs with business objectives.
Responsibilities:
● Develop and implement a comprehensive strategy for the portfolio of metabolic diseases including obesity and NASH.
● Provide leadership and guidance to cross-functional teams, fostering collaboration and innovation.
● Lead the design and execution of research and discovery programs, in-vitro experiments, and preclinical studies related to metabolic diseases.
● Oversee the identification and validation of novel therapeutic targets.
● Identify and cultivate relationships with key opinion leaders (KOLs) and academic researchers in the field of metabolic conditions.
Required Qualifications:
● Advanced degree (Ph.D. and/or M.D.) with 5+ years of relevant industry experience.
● Proven track record of scientific leadership in the metabolic diseases, demonstrated by establishing research programs leading to target validation, pre-clinical research, translational research, and IND-enabling studies.
● Experience with design and execution of experiments in animal models for metabolic conditions.
● Strong project management skills and ability to lead cross-functional teams.
● Strong track record of strong scientific research, demonstrated by high-quality publications, conference talks, and patents.
● Experience with cell and gene therapy and/or novel therapeutic modalities is preferred.
● Excellent communication skills with the ability to articulate complex technical concepts to various stakeholders.
About Moonwalk Biosciences:
Moonwalk Biosciences is pioneering a new class of precision epigenetic medicines. Its novel platform technology provides a complete view of the epigenome in health and disease, with the most advanced Al prediction of epigenetic targets, and the broadest set of epigenetic engineering tools. Moonwalk was Co-founded by Alex Aravanis, M.D., Ph.D., former CTO of Illumina, world-renowned scientist Feng Zhang, Ph.D. of the Broad Institute of MIT and Harvard, and a distinguished set of industry leaders and company builders. It has raised $57 million led by Alpha Wave Ventures, and joined by other leading life sciences investors ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures.